Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
Anthony
Navin
N
Department of Hematology and Oncology, Providence Hospital and Medical Centers, Southfield, MI, USA. navokc@yahoo.com
Shanks
James
J
Terebelo
Howard
H
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate